Rchr
J-GLOBAL ID:201101097064605496   Update date: Oct. 30, 2024

Ito Takumi

イトウ タクミ | Ito Takumi
Research field  (1): Molecular biochemistry
Research keywords  (6): ubiquitin ligase ,  cereblon ,  多発性骨髄腫 ,  IMiDs ,  サリドマイド ,  ケミカルバイオロジー
Research theme for competitive and other funds  (8):
  • 2023 - 2028 Controlling the lifetime of proteins using chemical degraders
  • 2021 - 2024 Elucidation of the therapeutic mechanisms of IMiDs
  • 2018 - 2023 Chemical protein knockdown technology and cell regulation
  • 2017 - 2020 Elucidation of the molecular basis of IMiDs' action
  • 2015 - 2019 代謝産物によるユビキチンリガーゼ制御工学の確立
Show all
Papers (50):
  • Kiwamu Hatakeyama, Yoshikane Kikushige, Daisuke Ishihara, Shunsuke Yamamoto, Gentaro Kawano, Taro Tochigi, Toshihiro Miyamoto, Teppei Sakoda, Andy Christoforou, Yuya Kunisaki, et al. Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drugs-induced thromboembolism. Blood advances. 2024
  • Takumi Ito. Protein degraders -from thalidomide to new PROTACs. The Journal of Biochemistry. 2023
  • Takumi Ito, Tomoko Asatsuma-Okumura, Akinori Endo, Junichi Yamamoto, Yoshiko Iwai, Yuki Yamaguchi, Mikihiko Naito, Hiroshi Handa, Yasushi Saeki. ZNF276 and WIZ are CRBN neosubstrates involved in the anti-angiogenic activity of thalidomide and immunomodulatory drugs. 2023
  • Akihiro Kimura, Takeshi Takagi, Thiprampai Thamamongood, Satoshi Sakamoto, Takumi Ito, Iwao Seki, Masahiro Okamoto, Hiroyuki Aono, Satoshi Serada, Tetsuji Naka, et al. Extracellular aaRSs drive autoimmune and inflammatory responses in rheumatoid arthritis via the release of cytokines and PAD4. Annals of the rheumatic diseases. 2023
  • Junichi Yamamoto, Tomoko Asatsuma-Okumura, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa. History of IMiDs and protein degradation as a pharmacological modality. Protein Homeostasis in Drug Discovery: A Chemical Biology Perspective. 2022. 285-315
more...
MISC (43):
  • 伊藤拓水, 伊藤拓水. Modulation of cereblon. 日本癌学会学術総会抄録集(Web). 2023. 82nd
  • 朝妻知子, 岩井佳子, 半田宏, 伊藤拓水. サリドマイド及びその誘導体の血管新生阻害作用機構の解明. 日本生化学会大会(Web). 2023. 96th
  • 朝妻知子, 伊藤拓水, 半田宏. HDAC阻害剤の抗骨髄腫作用に関する研究. 東京医科大学雑誌(Web). 2022. 80. 2
  • 伊藤拓水. Development of novel cereblon modulators and their target molecules. 臨床血液. 2022. 63. 6
  • 朝妻知子, 半田宏, 伊藤拓水. Development of new cereblon modulators and their target proteins. 月刊血液内科. 2022. 84. 4
more...
Patents (13):
Education (2):
  • 2004 - 2008 Tokyo Institute of Technology Graduate School of Bioscience and Biotechnology Department of Biological Information
  • 2000 - 2004 Tokyo Institute of Technology School of Bioscience and Biotechnology Department of Biosciences
Work history (4):
  • 2016/04 - 2022/03 Tokyo Medical University
  • 2013/10 - 2016/03 Tokyo Medical University
  • 2012/04 - 2013/09 Tokyo Institute of Technology Graduate School of Bioscience and Biotechnology
  • 2008/10 - 2012/03 Tokyo Institute of Technology Graduate School of Bioscience and Biotechnology
Awards (2):
  • 2012/02 - 井上科学振興財団 井上研究奨励賞
  • 2011/02 - 東京工業大学 手島精一記念研究賞(研究論文賞)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page